Publication date: Jun 18, 2024
The Panbio COVID-19/Flu A&B Panel (Abbott) is an in vitro diagnostic rapid test designed for the qualitative detection of nucleocapsid proteins SARS-CoV-2 and nucleoprotein influenza A and B antigens in nasal mid-turbinate (NMT) swab specimens from symptomatic individuals meeting COVID-19 and influenza clinical and/or epidemiological criteria. This study, the largest global one to date using fresh samples, aimed to assess the diagnostic sensitivity and specificity of the Panbio COVID-19/Flu A&B Panel in freshly collected NMT swab specimens from individuals suspected of respiratory viral infection consistent with COVID-19 and/or influenza within the first 5 days of symptom onset compared with results obtained with the cobas SARS-CoV-2 and influenza A/B qualitative assay (cobas 6800/8800 systems), which were tested using nasopharyngeal swab samples. A total of 512 evaluable subjects were enrolled in the COVID-19 cohort across 18 sites, and 1,148 evaluable subjects were enrolled in the influenza cohort across 22 sites in the Asia-Pacific, Europe, and the USA. The Panbio COVID-19/Flu A&B Panel demonstrated a sensitivity of 80. 4% and a specificity of 99. 7% for COVID-19. For influenza A, the sensitivity and specificity rates were 80. 6% and 99. 3%, respectively. Likewise, for influenza B, the sensitivity and specificity rates were 80. 8% and 99. 4%, respectively. In conclusion, the Panbio COVID-19/Flu A&B Panel emerges as a suitable rapid test for detecting COVID-19 and influenza in symptomatic subjects across diverse global populations, exhibiting high sensitivity. The assay achieved a sensitivity of 94. 4% in samples with Ct ≤24 for COVID-19 and 92. 6% in samples with Ct ≤30 for influenza A and B. The Panbio COVID-19/Flu A&B Panel is a suitable rapid test for detecting COVID-19 and influenza in symptomatic subjects across diverse global populations, exhibiting high sensitivity. The assay achieved a sensitivity of 94. 0% in samples with Ct ≤24 for COVID-19 and 92. 6% in samples with Ct ≤30 for influenza A and B.
Concepts | Keywords |
---|---|
Epidemiological | COVID-19 |
Freshly | SARS-CoV-2 |
Influenza | sensitivity |
Pacific | specificity |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
pathway | KEGG | Influenza A |
disease | MESH | influenza |
disease | MESH | viral infection |
disease | IDO | symptom |
disease | IDO | assay |
disease | VO | USA |
disease | MESH | Long Covid |